INOVIO PHARMACEUTICALS, INC. - 10-Q Summary (Q1 2026)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. INOVIO is a biotechnology company developing DNA medicines and proprietary delivery devices (CELLECTRA). The company's lead candidate, INO-3107, is an investigational DNA medicine for Recurrent Respiratory Papillomatosis (RRP). The FDA accepted the Biologic License Application (BLA) for INO-3107 in December 2025 for review under the accelerated approval program, with a PDUFA target date of October 30, 2026. However, the FDA denied a request for priority review and raised preliminary concerns regarding eligibility for the accelerated approval pathway.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $65,343 |
| Net Loss | $(19,682,798) | $(19,694,697) |
| Net Loss Per Share (Basic/Diluted) | $(0.28) | $(0.51) |
| Operating Expenses | $21,949,993 | $25,115,872 |
| Cash and Cash Equivalents | $26,271,650 | $39,915,447 |
| Short-term Investments | $11,409,607 | $14,239,145 |
| Total Liquidity (Cash + Investments) | $37,681,257 | $54,154,592 |
| Working Capital | $1,516,580 | $17,454,791 |
| Accumulated Deficit | $(1,834,847,961) | $(1,749,913,959) |
Material Changes vs. Prior Period
- Revenue: Revenue dropped to zero from $65,343 in Q1 2025, as the collaborative arrangement revenue from ApolloBio was not recognized in the current quarter.
- Operating Expenses: Total operating expenses decreased by approximately $3.2 million (13%) year-over-year, driven by lower employee compensation, engineering services, and stock-based compensation.
- Investment Loss: The company recorded a $2.1 million loss on its investment in affiliated entity Plumbline Life Sciences, Inc. (PLS). Trading of PLS stock was suspended, leading to a fair value reclassification to $0.
- Warrant Liability: A gain of $4.1 million was recorded due to the change in fair value of common stock warrant liabilities, primarily driven by the expiration of the July 2025 Series A Warrants.
- Liquidity: Cash and cash equivalents decreased by $18.0 million during the quarter due to operating cash outflows of $21.6 million.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern beyond the late fourth quarter of 2026. Current resources are expected to fund operations only into the first quarter of 2027.
- Regulatory Status: The FDA is reviewing the BLA for INO-3107. While no new significant issues were raised in the mid-cycle review, the FDA reiterated its intention to discuss eligibility for the accelerated approval pathway. If accelerated approval is denied, the company may need to conduct a costly Phase 3 trial.
- Capital Raise: Subsequent to the quarter-end, on April 6, 2026, the company closed an underwritten public offering raising $16.0 million in net proceeds. This was incorporated into the going concern analysis.
- Legal Proceedings: The company is facing a shareholder class action lawsuit and multiple derivative complaints alleging false statements regarding the FDA submission and review timeline for INO-3107. Additionally, litigation with former contract manufacturer VGXI remains pending.
- Competition: The FDA approved a competitor's product, PAPZIMEOS, for RRP in August 2025, which may impact the commercial landscape and regulatory pathway for INO-3107.
Investor Verification Checklist
- Regulatory Pathway: Verify the outcome of the upcoming FDA meeting regarding the eligibility of INO-3107 for the accelerated approval program.
- Cash Runway: Confirm the sufficiency of the $16.0 million raised in April 2026 combined with existing cash to fund operations through the anticipated Q1 2027 timeline.
- Legal Exposure: Monitor the status of the securities litigation and the VGXI counterclaims for potential financial impact.
- Investment Write-down: Review the valuation methodology used for the $2.1 million write-down of the Plumbline Life Sciences investment.
- Warrant Liability: Assess the impact of outstanding warrant liabilities (approx. $24.9 million) on future balance sheet volatility and potential dilution.